Until recently, there are no available preventive measures for macrovascular complications of diabetes mellitus (DM). Sodium-glucose co-transporter inhibitors (SGLT-2i) are a relatively new class of medications with cardio-renal protection. However, it is unknown, whether this is a class effect. Also, the exact mechanisms of action are not fully understood.
No takes yet. Share an insight, caveat, or question.
Altemani et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: